Research progress of related genes in Hashimoto’s thyroiditis with papillary thyroid carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

FU Jingyao , ZHANG Guangxu , LU Hongzhi , SHEN Keyu ,  ZHANG Guang

Department of Thyroid Surgery, China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Jilin Provincial Engineering Laboratory of Thyroid Disease Prevention and Control, Changchun 130033, P. R. China;

Corresponding author：

ZHANG Guang, Email: zhangguang@jlu.edu.cn

Keywords：

Hashimoto’s thyroiditis; papillary thyroid carcinoma; gene

DOI：

10.7507/1007-9424.202009115

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the research progress of related genes in Hashimoto’s thyroiditis with papillary thyroid carcinoma.Method Literatures about Hashimoto’s thyroiditis with papillary thyroid carcinoma were reviewed by searching the literatures in domestic and foreign database.Results In recent years, the incidence of Hashimoto’s thyroiditis with thyroid carcinoma (especially papillary thyroid carcinoma) was on the increase, the two might have the same molecular pathology mechanism.Conclusion There is a close association between Hashimoto’s thyroiditis and papillary thyroid carcinoma, the common molecular genetic changes suggest that Hashimoto’s thyroiditis may have a correlation with papillary thyroid carcinoma.

Citation： FU Jingyao, ZHANG Guangxu, LU Hongzhi, SHEN Keyu, ZHANG Guang. Research progress of related genes in Hashimoto’s thyroiditis with papillary thyroid carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(7): 956-961. doi: 10.7507/1007-9424.202009115 Copy

1.	Lim H, Devesa SS, Sosa JA, et al. Trends in thyroid cancer incidence and mortality in the united states, 1974–2013. JAMA, 2017, 317(13): 1338-1348.
2.	Zhu X, Yao J, Tian W. Microarray technology to investigate genes associated with papillary thyroid carcinoma. Mol Med Rep, 2015, 11(5): 3729-3733.
3.	Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Archives Surg, 1955, 70(2): 291-297.
4.	周晓倩, 刘俊, 金慧, 等. 桥本甲状腺炎与甲状腺乳头状癌的关系研究. 中国医师杂志, 2015, 17(10): 1578-1579.
5.	Molnár C, Molnár S, Bedekovics J, et al. Thyroid carcinoma coexisting with Hashimoto’s thyreoiditis: clinicopathological and molecular characteristics clue up pathogenesis. Pathol Oncol Res, 2019, 25(3): 1191-1197.
6.	Uhliarova B, Hajtman A. Hashimoto’s thyroiditis—an independent risk factor for papillary carcinoma. Braz J Otorhinolaryngol, 2018, 84(6): 729-735.
7.	李浩, 李华玉, 唐金涛, 等. 分化型甲状腺癌伴与不伴慢性淋巴细胞性甲状腺炎的临床对比. 临床与病理杂志, 2020, 40(6): 1376-1381.
8.	Graceffa G, Patrone R, Vieni S, et al. Association between Hashimoto’s thyroiditis and papillary thyroid carcinoma: a retrospective analysis of 305 patients. BMC Endocr Disord, 2019, 19(Suppl 1): 26.
9.	张广, 边学海, 李世杰, 等. 甲状腺炎合并甲状腺癌 210 例诊治分析. 中国实用外科杂志, 2011, 31(6): 525-526, 529.
10.	Zhang Y, Dai J, Wu T, et al. The study of the coexistence of Hashimoto’s thyroiditis with papillary thyroid carcinoma. J Cancer Res Clin Oncol, 2014, 140(6): 1021-1026.
11.	Silva de Morais N, Stuart J, Guan H, et al. The impact of Hashimoto thyroiditis on thyroid nodule cytology and risk of thyroid cancer. J Endocr Soc, 2019, 3(4): 791-800.
12.	Pyzik A, Grywalska E, Matyjaszek-Matuszek B, et al. Immune disorders in Hashimoto’s thyroiditis: what do we know so far? J Immunol Res, 2015, 2015: 979167.
13.	Anand A, Singh KR, Kushwaha JK, et al. Papillary thyroid cancer and Hashimoto’s thyroiditis: An association less understood. Indian J Surg Oncol, 2014, 5(3): 199-204.
14.	Fussey JM, Beaumont RN, Wood AR, et al. Mendelian randomization supports a causative effect of TSH on thyroid carcinoma. Endocr Relat Cancer, 2020, 27(10): 551-559.
15.	Rayman MP. Multiple nutritional factors and thyroid disease, with particular reference to autoimmune thyroid disease. Proc Nutr Soc, 2019, 78(1): 34-44.
16.	Farebrother J, Zimmermann MB, Andersson M. Excess iodine intake: sources, assessment, and effects on thyroid function. Ann N Y Acad Sci, 2019, 1446(1): 44-65.
17.	王翔, 尹雅楠, 孔姿莉, 等. 分化型甲状腺癌肿瘤局部免疫细胞亚群与其复发关系. 青岛大学学报(医学版), 2020, 56(5): 566-570.
18.	Shi L, Zhou L, Wang J, et al. Cytokine production of papillary thyroid carcinoma coexisting with Hashimoto’s thyroiditis. Int J Clin Exp Pathol, 2017, 10(9): 9567-9574.
19.	Ellyard JI, Simson L, Parish CR. Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens, 2007, 70(1): 1-11.
20.	Miccoli P, Torregrossa L, Borrelli N, et al. E-selectin expression and BRAF status in papillary thyroid carcinomas: Correlation with clinicopathologic features. Surgery, 2014, 156(6): 1550-1558.
21.	Ehlers M, Schott M. Hashimoto’s thyroiditis and papillary thyroid cancer: are they immunologically linked? Trends Endocrinol Metab, 2014, 25(12): 656-664.
22.	Arif S, Blanes A, Diaz-Cano SJ. Hashimoto’s thyroiditis shares features with early papillary thyroid carcinoma. Histopathology, 2002, 41(4): 357-362.
23.	鲁海珍, 张楠, 刘皖, 等. 伴和不伴有桥本甲状腺炎的甲状腺乳头状癌的蛋白表达差异. 中华肿瘤杂志, 2020, 42(6): 463-468.
24.	Royer MC, Zhang H, Fan CY, et al. Genetic alterations in papillary thyroid carcinoma and hashimoto thyroiditis: An analysis of hOGG1 loss of heterozygosity. Arch Otolaryngol Head Neck Surg, 2010, 136(3): 240-242.
25.	Larson SD, Jackson LN, Riall TS, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg, 2007, 204(5): 764-775.
26.	Divani SN, Kalodimos GP, Lioupis MA, et al. Hashimoto’s thyroiditis and papillary thyroid carcinoma. Are cytokeratin 19 and P63 proteins of any diagnostic value? Hell J Nucl Med, 2016, 19(3): 250-253.
27.	Kumarasamy VM, Shin YJ, White J, et al. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine. BMC Cancer, 2015, 15: 599.
28.	Staubitz JI, Schad A, Springer E, et al. Novel rearrangements involving the RET gene in papillary thyroid carcinoma. Cancer Genet, 2019, 230: 13-20.
29.	Punda A, Bedeković V, Barić A, et al. RET expression and its correlation with clinicopathologic data in papillary thyroid carcinoma. Acta Clin Croat, 2018, 57(4): 646-652.
30.	Abdullah MI, Junit SM, Ng KL, et al. Papillary thyroid cancer: genetic alterations and molecular biomarker investigations. Int J Med Sci, 2019, 16(3): 450-460.
31.	Rhoden KJ, Unger K, Salvatore G, et al. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto’s thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab, 2006, 91(6): 2414-2423.
32.	Pufnock JS, Rothstein JL. Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression. J Immunol, 2009, 182(9): 5498-5506.
33.	Gupta A, Jain S, Khurana N, et al. Expression of p63 and Bcl-2 in malignant thyroid tumors and their correlation with other diagnostic immunocytochemical markers. J Clin Diagn Res, 2016, 10(7): EC04-EC08.
34.	Manzella L, Stella S, Pennisi MS, et al. New insights in thyroid cancer and p53 family proteins. Int J Mol Sci, 2017, 18(6): 1325.
35.	魏涛, 朱精强. p53基因家族与甲状腺癌的相关研究进展. 中国普外基础与临床杂志, 2019, 26(11): 1372-1377.
36.	Burstein DE, Nagi C, Wang BY, et al. Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and hashimoto’s thyroiditis: a stem cell hypothesis of papillary carcinoma oncogenesis. Hum Pathol, 2004, 35(4): 465-473.
37.	Jankovic B, Le KT, Hershman JM. Clinical review: Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab, 2013, 98(2): 474-482.
38.	何榕洲, 江瑜, 余济春, 等. BRAF 基因与甲状腺癌关系的研究进展. 中华外科杂志, 2016, 54(3): 237-240.
39.	Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol, 2015, 16(5): 281-298.
40.	Yan C, Huang M, Li X, et al. Relationship between BRAF^V600E and clinical features in papillary thyroid carcinoma. Endocr Connect, 2019, 8(7): 988-996.
41.	Zhang Q, Liu SZ, Zhang Q, et al. Meta-analyses of association between BRAF^V600Emutation and clinicopathological features of papillary thyroid carcinoma. Cell Physiol Biochem, 2016, 38(2): 763-776.
42.	Kim SJ, Myong JP, Jee HG, et al. Combined effect of Hashimoto’s thyroiditis and BRAF^V600E mutation status on aggressiveness in papillary thyroid cancer. Head Neck, 2016, 38(1): 95-101.
43.	Pessôa-Pereira D, Medeiros MFDS, Lima VMS, et al. Association between BRAF^V600E mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series. Arch Endocrinol Metab, 2019, 63(2): 97-106.
44.	Noorolyai S, Shajari N, Baghbani E, et al. The relation between PI3K/AKT signalling pathway and cancer. Gene, 2019, 698: 120-128.
45.	史晓莉, 申红梅. PI3K/AKT 信号通路相关基因拷贝数变异与甲状腺癌关系的研究进展. 中华地方病学杂志, 2019, 38(1): 83-86.
46.	Robbins HL, Hague A. The PI3K/Akt pathway in tumors of endocrine tissues. Front Endocrinol (Lausanne), 2016, 6: 188.
47.	Xin Y, Guan D, Meng K, et al. Diagnostic accuracy of CK-19, Galectin-3 and HBME-1 on papillary thyroid carcinoma: a meta-analysis. Int J Clin Exp Pathol, 2017, 10(8): 8130-8140.
48.	Abouhashem NS, Talaat SM. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics. Pathol Res Pract, 2017, 213(5): 509-517.
49.	Dong S, Xie XJ, Xia Q, et al. Indicators of multifocality in papillary thyroid carcinoma concurrent with Hashimoto’s thyroiditis. Am J Cancer Res, 2019, 9(8): 1786-1795.
50.	Cho H, Kim JY, Oh YL. Diagnostic value of HBME-1, CK19, Galectin 3, and CD56 in the subtypes of follicular variant of papillary thyroid carcinoma. Pathol Int, 2018, 68(11): 605-613.
51.	Ma H, Yan J, Zhang C, et al. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto’s thyroiditis. Int J Clin Exp Pathol, 2014, 7(11): 7999-8007.
52.	Mohamed SY, Ibrahim TR, Elbasateeny SS, et al. Clinicopathological characterization and prognostic implication of FOXP3 and CK19 expression in papillary thyroid carcinoma and concomitant Hashimoto’s thyroiditis. Sci Rep, 2020, 10(1): 10651.
53.	Ma Y, He J, Shen N, et al. Expression of NIS, VEGF-A and thyroid autoantibody in papillary thyroid carcinoma with or without Hashimoto’s disease. ORL J Otorhinolaryngol Relat Spec, 2019, 81(5-6): 281-286.
54.	Mohamad Pakarul Razy NH, Wan Abdul Rahman WF, Win TT. Expression of vascular endothelial growth factor and its receptors in thyroid nodular hyperplasia and papillary thyroid carcinoma: A tertiary health care centre based study. Asian Pac J Cancer Prev, 2019, 20(1): 277-282.
55.	Abbasalizad Farhangi M, Tajmiri S. The correlation between inflammatory and metabolic parameters with thyroid function in patients with Hashimoto’s thyroiditis: the potential role of interleukin 23 (IL-23) and vascular endothelial growth factor (VEGF)-1. Acta Endocrinol (Buchar), 2018, 14(2): 163-168.

1. Lim H, Devesa SS, Sosa JA, et al. Trends in thyroid cancer incidence and mortality in the united states, 1974–2013. JAMA, 2017, 317(13): 1338-1348.
2. Zhu X, Yao J, Tian W. Microarray technology to investigate genes associated with papillary thyroid carcinoma. Mol Med Rep, 2015, 11(5): 3729-3733.
3. Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Archives Surg, 1955, 70(2): 291-297.
4. 周晓倩, 刘俊, 金慧, 等. 桥本甲状腺炎与甲状腺乳头状癌的关系研究. 中国医师杂志, 2015, 17(10): 1578-1579.
5. Molnár C, Molnár S, Bedekovics J, et al. Thyroid carcinoma coexisting with Hashimoto’s thyreoiditis: clinicopathological and molecular characteristics clue up pathogenesis. Pathol Oncol Res, 2019, 25(3): 1191-1197.
6. Uhliarova B, Hajtman A. Hashimoto’s thyroiditis—an independent risk factor for papillary carcinoma. Braz J Otorhinolaryngol, 2018, 84(6): 729-735.
7. 李浩, 李华玉, 唐金涛, 等. 分化型甲状腺癌伴与不伴慢性淋巴细胞性甲状腺炎的临床对比. 临床与病理杂志, 2020, 40(6): 1376-1381.
8. Graceffa G, Patrone R, Vieni S, et al. Association between Hashimoto’s thyroiditis and papillary thyroid carcinoma: a retrospective analysis of 305 patients. BMC Endocr Disord, 2019, 19(Suppl 1): 26.
9. 张广, 边学海, 李世杰, 等. 甲状腺炎合并甲状腺癌 210 例诊治分析. 中国实用外科杂志, 2011, 31(6): 525-526, 529.
10. Zhang Y, Dai J, Wu T, et al. The study of the coexistence of Hashimoto’s thyroiditis with papillary thyroid carcinoma. J Cancer Res Clin Oncol, 2014, 140(6): 1021-1026.
11. Silva de Morais N, Stuart J, Guan H, et al. The impact of Hashimoto thyroiditis on thyroid nodule cytology and risk of thyroid cancer. J Endocr Soc, 2019, 3(4): 791-800.
12. Pyzik A, Grywalska E, Matyjaszek-Matuszek B, et al. Immune disorders in Hashimoto’s thyroiditis: what do we know so far? J Immunol Res, 2015, 2015: 979167.
13. Anand A, Singh KR, Kushwaha JK, et al. Papillary thyroid cancer and Hashimoto’s thyroiditis: An association less understood. Indian J Surg Oncol, 2014, 5(3): 199-204.
14. Fussey JM, Beaumont RN, Wood AR, et al. Mendelian randomization supports a causative effect of TSH on thyroid carcinoma. Endocr Relat Cancer, 2020, 27(10): 551-559.
15. Rayman MP. Multiple nutritional factors and thyroid disease, with particular reference to autoimmune thyroid disease. Proc Nutr Soc, 2019, 78(1): 34-44.
16. Farebrother J, Zimmermann MB, Andersson M. Excess iodine intake: sources, assessment, and effects on thyroid function. Ann N Y Acad Sci, 2019, 1446(1): 44-65.
17. 王翔, 尹雅楠, 孔姿莉, 等. 分化型甲状腺癌肿瘤局部免疫细胞亚群与其复发关系. 青岛大学学报(医学版), 2020, 56(5): 566-570.
18. Shi L, Zhou L, Wang J, et al. Cytokine production of papillary thyroid carcinoma coexisting with Hashimoto’s thyroiditis. Int J Clin Exp Pathol, 2017, 10(9): 9567-9574.
19. Ellyard JI, Simson L, Parish CR. Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens, 2007, 70(1): 1-11.
20. Miccoli P, Torregrossa L, Borrelli N, et al. E-selectin expression and BRAF status in papillary thyroid carcinomas: Correlation with clinicopathologic features. Surgery, 2014, 156(6): 1550-1558.
21. Ehlers M, Schott M. Hashimoto’s thyroiditis and papillary thyroid cancer: are they immunologically linked? Trends Endocrinol Metab, 2014, 25(12): 656-664.
22. Arif S, Blanes A, Diaz-Cano SJ. Hashimoto’s thyroiditis shares features with early papillary thyroid carcinoma. Histopathology, 2002, 41(4): 357-362.
23. 鲁海珍, 张楠, 刘皖, 等. 伴和不伴有桥本甲状腺炎的甲状腺乳头状癌的蛋白表达差异. 中华肿瘤杂志, 2020, 42(6): 463-468.
24. Royer MC, Zhang H, Fan CY, et al. Genetic alterations in papillary thyroid carcinoma and hashimoto thyroiditis: An analysis of hOGG1 loss of heterozygosity. Arch Otolaryngol Head Neck Surg, 2010, 136(3): 240-242.
25. Larson SD, Jackson LN, Riall TS, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg, 2007, 204(5): 764-775.
26. Divani SN, Kalodimos GP, Lioupis MA, et al. Hashimoto’s thyroiditis and papillary thyroid carcinoma. Are cytokeratin 19 and P63 proteins of any diagnostic value? Hell J Nucl Med, 2016, 19(3): 250-253.
27. Kumarasamy VM, Shin YJ, White J, et al. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine. BMC Cancer, 2015, 15: 599.
28. Staubitz JI, Schad A, Springer E, et al. Novel rearrangements involving the RET gene in papillary thyroid carcinoma. Cancer Genet, 2019, 230: 13-20.
29. Punda A, Bedeković V, Barić A, et al. RET expression and its correlation with clinicopathologic data in papillary thyroid carcinoma. Acta Clin Croat, 2018, 57(4): 646-652.
30. Abdullah MI, Junit SM, Ng KL, et al. Papillary thyroid cancer: genetic alterations and molecular biomarker investigations. Int J Med Sci, 2019, 16(3): 450-460.
31. Rhoden KJ, Unger K, Salvatore G, et al. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto’s thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab, 2006, 91(6): 2414-2423.
32. Pufnock JS, Rothstein JL. Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression. J Immunol, 2009, 182(9): 5498-5506.
33. Gupta A, Jain S, Khurana N, et al. Expression of p63 and Bcl-2 in malignant thyroid tumors and their correlation with other diagnostic immunocytochemical markers. J Clin Diagn Res, 2016, 10(7): EC04-EC08.
34. Manzella L, Stella S, Pennisi MS, et al. New insights in thyroid cancer and p53 family proteins. Int J Mol Sci, 2017, 18(6): 1325.
35. 魏涛, 朱精强. p53基因家族与甲状腺癌的相关研究进展. 中国普外基础与临床杂志, 2019, 26(11): 1372-1377.
36. Burstein DE, Nagi C, Wang BY, et al. Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and hashimoto’s thyroiditis: a stem cell hypothesis of papillary carcinoma oncogenesis. Hum Pathol, 2004, 35(4): 465-473.
37. Jankovic B, Le KT, Hershman JM. Clinical review: Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab, 2013, 98(2): 474-482.
38. 何榕洲, 江瑜, 余济春, 等. BRAF 基因与甲状腺癌关系的研究进展. 中华外科杂志, 2016, 54(3): 237-240.
39. Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol, 2015, 16(5): 281-298.
40. Yan C, Huang M, Li X, et al. Relationship between BRAF^V600E and clinical features in papillary thyroid carcinoma. Endocr Connect, 2019, 8(7): 988-996.
41. Zhang Q, Liu SZ, Zhang Q, et al. Meta-analyses of association between BRAF^V600Emutation and clinicopathological features of papillary thyroid carcinoma. Cell Physiol Biochem, 2016, 38(2): 763-776.
42. Kim SJ, Myong JP, Jee HG, et al. Combined effect of Hashimoto’s thyroiditis and BRAF^V600E mutation status on aggressiveness in papillary thyroid cancer. Head Neck, 2016, 38(1): 95-101.
43. Pessôa-Pereira D, Medeiros MFDS, Lima VMS, et al. Association between BRAF^V600E mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series. Arch Endocrinol Metab, 2019, 63(2): 97-106.
44. Noorolyai S, Shajari N, Baghbani E, et al. The relation between PI3K/AKT signalling pathway and cancer. Gene, 2019, 698: 120-128.
45. 史晓莉, 申红梅. PI3K/AKT 信号通路相关基因拷贝数变异与甲状腺癌关系的研究进展. 中华地方病学杂志, 2019, 38(1): 83-86.
46. Robbins HL, Hague A. The PI3K/Akt pathway in tumors of endocrine tissues. Front Endocrinol (Lausanne), 2016, 6: 188.
47. Xin Y, Guan D, Meng K, et al. Diagnostic accuracy of CK-19, Galectin-3 and HBME-1 on papillary thyroid carcinoma: a meta-analysis. Int J Clin Exp Pathol, 2017, 10(8): 8130-8140.
48. Abouhashem NS, Talaat SM. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics. Pathol Res Pract, 2017, 213(5): 509-517.
49. Dong S, Xie XJ, Xia Q, et al. Indicators of multifocality in papillary thyroid carcinoma concurrent with Hashimoto’s thyroiditis. Am J Cancer Res, 2019, 9(8): 1786-1795.
50. Cho H, Kim JY, Oh YL. Diagnostic value of HBME-1, CK19, Galectin 3, and CD56 in the subtypes of follicular variant of papillary thyroid carcinoma. Pathol Int, 2018, 68(11): 605-613.
51. Ma H, Yan J, Zhang C, et al. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto’s thyroiditis. Int J Clin Exp Pathol, 2014, 7(11): 7999-8007.
52. Mohamed SY, Ibrahim TR, Elbasateeny SS, et al. Clinicopathological characterization and prognostic implication of FOXP3 and CK19 expression in papillary thyroid carcinoma and concomitant Hashimoto’s thyroiditis. Sci Rep, 2020, 10(1): 10651.
53. Ma Y, He J, Shen N, et al. Expression of NIS, VEGF-A and thyroid autoantibody in papillary thyroid carcinoma with or without Hashimoto’s disease. ORL J Otorhinolaryngol Relat Spec, 2019, 81(5-6): 281-286.
54. Mohamad Pakarul Razy NH, Wan Abdul Rahman WF, Win TT. Expression of vascular endothelial growth factor and its receptors in thyroid nodular hyperplasia and papillary thyroid carcinoma: A tertiary health care centre based study. Asian Pac J Cancer Prev, 2019, 20(1): 277-282.
55. Abbasalizad Farhangi M, Tajmiri S. The correlation between inflammatory and metabolic parameters with thyroid function in patients with Hashimoto’s thyroiditis: the potential role of interleukin 23 (IL-23) and vascular endothelial growth factor (VEGF)-1. Acta Endocrinol (Buchar), 2018, 14(2): 163-168.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research progress of related genes in Hashimoto’s thyroiditis with papillary thyroid carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content